Loading
Filamon, an Australian company working on long-term inflammatory diseases of ageing, is testing a new type of drug in solid tumours that aims to stop cancer cells changing into a form that spreads.
Filamon Ltd (ACN 630 721 783), based in Hawthorn East, Melbourne, develops drugs aimed at what it calls master switches of chronic inflammation, across cancer, fibrotic disease, eye disease and other age-related conditions. In oncology, KESONOTIDE and ALPHA-D3 are described by the company as a new class of chemotherapy acting through EGFR degradation and vimentin inhibition to block the epithelial-mesenchymal transition. KESONOTIDE, which the registry calls a novel hGIIA-vimentin inhibitor, is in an adaptive phase 1/2 study in solid tumours including prostate and breast cancer (NCT06926075). Its first registered cancer trial, NCT06926075, was posted on ClinicalTrials.gov in April 2025.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/